Novavax expands COVID-19 vaccine study to include children aged 12 to 17
The global fight against the COVID-19 pandemic has been marked by the development and distribution of various vaccines. As the vaccination campaigns continue worldwide, the focus has shifted to include younger age groups, particularly children aged 12 to 17. One notable player in this endeavor is Novavax. In response to growing concerns about the virus’s impact on adolescents, Novavax has expanded its COVID-19 vaccine study to include children aged 12 to 17. Expanding the scope Novavax has made significant strides in its vaccine research and development. While their vaccine has been authorized for emergency use in various countries for adults, the company recognizes the importance of extending protection to younger age groups. To address this need, Novavax initiated a study focusing on adolescents aged 12 to 17. This expansion marks a crucial step in the ongoing battle against the pandemic. Contributing to herd immunity Novavax’s COVID-19 vaccine candidate has displayed encouraging results in clinical trials conducted on adults. Its unique protein-based technology, known as recombinant nanoparticle technology, has triggered an immune response against the virus. The expansion of the study to adolescents demonstrates the company’s confidence in the vaccine’s potential benefits for this age group. Ensuring the safety and efficacy of vaccines in younger age groups is of paramount importance.
Read More